Today: 23 January 2026
Subscribe

Khadija Saeed

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

Opendoor (OPEN) Stock Today: Price, News, Warrant Dividend and Outlook – November 20, 2025

Opendoor (OPEN) Stock Today: Price, News, Warrant Dividend and Outlook – November 20, 2025

Opendoor Technologies’ stock is back in the spotlight as a slowing housing market collides with meme‑stock style volatility, a new “shareholder‑first” warrant dividend, and an aggressive AI‑driven turnaround plan. Key Takeaways for OPEN Stock Today (November 20, 2025) OPEN Stock Price Today: How the Market is Trading Opendoor As of late trading on Thursday, November 20, 2025, Opendoor shares were…
20 November 2025
··
Marvell Technology (MRVL) Stock Today: AI Expansion in India Meets Wall Street Volatility – November 20, 2025

Marvell Technology (MRVL) Stock Today: AI Expansion in India Meets Wall Street Volatility – November 20, 2025

Published: November 20, 2025 – All prices as of U.S. market close / early post‑market Marvell Technology (NASDAQ: MRVL) shares were caught in Thursday’s sharp tech sell‑off, sliding even as the chipmaker unveiled fresh plans to expand its AI footprint in India and investors gear up for its next earnings report on December 2. By the closing bell, MRVL stock…
20 November 2025
··
Ondas Holdings (ONDS) Stock Today, November 20, 2025: Big Swings After $35 Million Combat Drone Deal and Share Authorization Vote

Ondas Holdings (ONDS) Stock Today, November 20, 2025: Big Swings After $35 Million Combat Drone Deal and Share Authorization Vote

Ondas Holdings Inc. (NASDAQ: ONDS) — the autonomous drones and private wireless company — is having another turbulent session today as Wall Street digests a fresh $35 million combat robotics investment and a key shareholder vote that dramatically expands the company’s capacity to issue new shares. As of late trading on Thursday, November 20, 2025, ONDS is changing hands around…
20 November 2025
··
JOYY Stock Today, November 20, 2025: 6% Rally After Earnings Beat, Dividend Hike and Strong Ad Growth

JOYY Stock Today, November 20, 2025: 6% Rally After Earnings Beat, Dividend Hike and Strong Ad Growth

JOYY stock price today: a standout among social media names Shares of JOYY Inc. (NASDAQ: JOYY), the Singapore‑based owner of Bigo Live, Likee, Hago and imo, are sharply higher on Thursday after the company reported third‑quarter 2025 results, raised its dividend and guided to higher revenue in the coming quarter. As of roughly mid‑afternoon on November 20, 2025 (3:45 p.m.…
20 November 2025
··
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax SA (NASDAQ: ABVX), the French biotech behind the inflammatory bowel disease drug candidate obefazimod, is back on traders’ screens today as the stock spikes on fresh takeover chatter involving pharma giant AstraZeneca. As of mid‑afternoon U.S. trading on Thursday, November 20, 2025, ABVX stock is trading around $121.94, up roughly 8% from Wednesday’s close of $112.95. Intraday, shares have…
20 November 2025
···
Kulicke & Soffa (KLIC) Jumps 11% After Q4 2025 Earnings Beat and Upbeat 2026 Guidance

Kulicke & Soffa (KLIC) Jumps 11% After Q4 2025 Earnings Beat and Upbeat 2026 Guidance

November 20, 2025 — KLIC stock update Kulicke & Soffa Industries, Inc. (NASDAQ: KLIC) is trading sharply higher on Thursday after the semiconductor assembly equipment maker delivered a better‑than‑expected fourth‑quarter report and a stronger outlook for early fiscal 2026. As of early afternoon trading on November 20, KLIC shares are around $39.23, up roughly 11% on the day, with an…
20 November 2025
··
1 … 780 781 782

Stock Market Today

  • Oric Pharmaceuticals Shares Poised for 74% Upside as Biotech Innovation Draws Investor Attention
    January 23, 2026, 8:13 AM EST. Oric Pharmaceuticals (NASDAQ: ORIC) is gaining investor interest with a potential 74% upside from its current $12.05 share price, backed by partnerships with Pfizer, Bayer, and Johnson & Johnson. The clinical-stage biotech focuses on therapies addressing cancer treatment resistance, advancing candidates like ORIC-114 and ORIC-944 through early-stage trials. Despite a $1.17 billion market cap, Oric reports a negative EPS of -1.71 and free cash flow of -$70.7 million, reflecting typical high-risk biotech dynamics. With no dividends and a neutral RSI, stock momentum shows cautious optimism. Analysts rate ORIC with 14 buys and project a $21 average target price, suggesting substantial growth for investors able to tolerate the sector's inherent uncertainties.
Go toTop